220 related articles for article (PubMed ID: 18794123)
21. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.
Krejci P; Murakami S; Prochazkova J; Trantirek L; Chlebova K; Ouyang Z; Aklian A; Smutny J; Bryja V; Kozubik A; Wilcox WR
J Biol Chem; 2010 Jul; 285(27):20644-53. PubMed ID: 20439987
[TBL] [Abstract][Full Text] [Related]
22. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
[TBL] [Abstract][Full Text] [Related]
23. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
[TBL] [Abstract][Full Text] [Related]
24. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
25. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.
Guo C; Degnin CR; Laederich MB; Lunstrum GP; Holden P; Bihlmaier J; Krakow D; Cho YJ; Horton WA
Cell Signal; 2008 Aug; 20(8):1471-7. PubMed ID: 18485666
[TBL] [Abstract][Full Text] [Related]
26. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
St-Germain JR; Taylor P; Tong J; Jin LL; Nikolic A; Stewart II; Ewing RM; Dharsee M; Li Z; Trudel S; Moran MF
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20127-32. PubMed ID: 19901323
[TBL] [Abstract][Full Text] [Related]
27. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
28. Mutations causing achondroplasia and thanatophoric dysplasia alter bFGF-induced calcium signals in human diploid fibroblasts.
Nguyen HB; Estacion M; Gargus JJ
Hum Mol Genet; 1997 May; 6(5):681-8. PubMed ID: 9158142
[TBL] [Abstract][Full Text] [Related]
29. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
[TBL] [Abstract][Full Text] [Related]
30. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation.
Gibbs L; Legeai-Mallet L
Biochim Biophys Acta; 2007 Apr; 1773(4):502-12. PubMed ID: 17320202
[TBL] [Abstract][Full Text] [Related]
31. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.
Lievens PM; Roncador A; Liboi E
J Mol Biol; 2006 Mar; 357(3):783-92. PubMed ID: 16476447
[TBL] [Abstract][Full Text] [Related]
32. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
33. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
[TBL] [Abstract][Full Text] [Related]
34. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
Iwata T; Li CL; Deng CX; Francomano CA
Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
[TBL] [Abstract][Full Text] [Related]
35. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
36. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
37. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
[TBL] [Abstract][Full Text] [Related]
38. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.
Hart KC; Robertson SC; Donoghue DJ
Mol Biol Cell; 2001 Apr; 12(4):931-42. PubMed ID: 11294897
[TBL] [Abstract][Full Text] [Related]
39. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.
Nowroozi N; Raffioni S; Wang T; Apostol BL; Bradshaw RA; Thompson LM
Hum Mol Genet; 2005 Jun; 14(11):1529-38. PubMed ID: 15843401
[TBL] [Abstract][Full Text] [Related]
40. Measurement of FGFR3 signaling at the cell membrane via total internal reflection fluorescence microscopy to compare the activation of FGFR3 mutants.
Hartl I; Brumovska V; Striedner Y; Yasari A; Schütz GJ; Sevcsik E; Tiemann-Boege I
J Biol Chem; 2023 Feb; 299(2):102832. PubMed ID: 36581204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]